MoonLake Immunotherapeutics (MLTX) financial statements
Net income was -$227M.
Free cash flow was -$196M.
The diluted share count rose 440% over the period (dilution).
Income statement
Fiscal years, from MoonLake Immunotherapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Research and development | — | $42M | $32M | $113M | $203M |
| Selling, general and admin | $5M | $23M | $22M | $30M | $42M |
| Operating income | -$5M | -$65M | -$54M | -$143M | -$245M |
| Interest expense | — | — | $0 | $0 | $7M |
| Pre-tax income | — | -$64M | -$44M | -$121M | -$230M |
| Income tax | — | $36,366 | $94,000 | $282,000 | $611,000 |
| Net income | -$5M | -$50M | -$36M | -$119M | -$227M |
| EPS (diluted) | -$0.31 | -$1.70 | -$0.73 | -$1.89 | -$3.53 |
| Diluted shares | 12M | 29M | 49M | 63M | 64M |
Balance sheet
Fiscal years, from MoonLake Immunotherapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and short-term investments | $8M | $72M | $511M | $448M | $394M |
| Total current assets | $10M | $77M | $514M | $474M | $422M |
| Property, plant and equipment | $45,739 | $49,389 | $320,865 | $722,000 | $577,000 |
| Total assets | $10M | $77M | $527M | $478M | $424M |
| Total current liabilities | $21M | $8M | $10M | $22M | $45M |
| Total liabilities | $21M | $8M | $13M | $25M | $120M |
| Shareholders' equity | -$12M | $49M | $496M | $447M | $304M |
| Net debt | -$8M | -$40M | -$451M | -$180M | -$335M |
Cash flow
Fiscal years, from MoonLake Immunotherapeutics's 10-K filings with the SEC.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$611,071 | -$56M | -$43M | -$117M | -$196M |
| Capital spending | — | $16,009 | $284,000 | $520,000 | $35,000 |
| Free cash flow | — | -$56M | -$43M | -$117M | -$196M |
| Stock-based compensation | — | $10M | $7M | $7M | $13M |
| Share buybacks (net) | — | $0 | $0 | -$50 | — |
| Net borrowing | — | — | $0 | $0 | $73M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MLTX.
Open MLTX in InvestinglyQuestions
How much free cash flow does MoonLake Immunotherapeutics generate?
-$196M in fiscal 2025 (operating cash flow minus capital spending).
From MoonLake Immunotherapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.